HemoCue honor World Diabetes Day and access to care for everyone.

HemoCue honor World Diabetes Day. We do so by recognizing the patients, their families, and the societies they belong to. But we do so also by recognizing, the physicians, nurses, organizations, governments, pharma companies, logistical partners and all our colleagues around the world– all those involved in providing diabetes care – and access to diabetes care. It is a teamwork, in partnership and collaboration -together we can, and are determined to, be part of making a difference.

World Diabetes Day 2021-2023: access to diabetes care

Celebrated on November 14, the World Diabetes Day calls to the international diabetes community to unite and draw attention to issues of utmost importance to the diabetes community. The International Diabetes Federation (IDF) and the World Health Organization (WHO) initiated the world’s largest diabetes awareness campaign in 1991, with the aim of keeping the metabolic disease firmly in the public and political spotlight. Since then, further activities have been, and continues to be done. Most recently the WHO launched Diabetes Compact at the 100 years anniversary of the discovery of insulin, April 14, 2021. The theme for World Diabetes Day 2021-23 is Access to diabetes care. Access to care -for everyone.

We wholeheartedly support this. We do so the way we can. By sharing our knowledge, our experience, and the value we can add in providing HemoCue essential diagnostics. These includes our diabetes portfolio that aids in making diagnostic decisions, and we strive to make these available, affordable, and accessible on a global scale.

As Lena Wahlhed, Director Global Alliances of HemoCue says, together with the tool to detect and monitor diabetes, with the tools available to treat -diabetes organizations and the health care community can extend their medical knowledge with diagnostic insight. At the point of care! This has proven to enhance compliance to treatment and may improve quality of life.

Lab-quality point-of-care testing improves clinical outcomes

HemoCue’s sustainable essential diagnostics plays an important role in non-communicable diseases such as diabetes. To have lab-quality test results while the patient is still in the doctor’s office, facilitates immediate medical decisions and may improve patient outcomes. These face-to-face discussions can enhance patient-doctor dialogue, further improve patient satisfaction and lead to enhanced compliance to treatment.

Studies have shown that HbA1c testing at the point-of-care:

• May increase compliance to treatment following recommendations for HbA1c testing frequency and treatment adoption
• may improves clinical outcomes
• facilitates patient education and motivation
• may improve patient´s quality of life and prevent diabetes associated complications
• may contribute to cost/time savings both for healthcare professionals and patients – and for their families, community, and society

To learn more about HemoCue visit www.hemocue.com

Contact information HemoCue

joakim.hagvik@hemocue.se Global Product Manager Diabetes

Lena.Wahlhed@hemocue.se Director Alliance Development

HemoCue AB | Kuvettgatan 1 | SE-262 71 | Ängelholm | Sweden | Phone: +46 77 570 02 10 | Fax: +46 77 570 02 12 | Org. No.: 5563429272